We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
-5.05%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
(-4.4%)
Cap. Flow
-$1B
Cap. Flow
% of AUM
-29.65%
Top 10 Holdings %
Top 10 Hldgs %
37.46%
Holding
95
New
13
Increased
23
Reduced
14
Closed
19
Top Buys
| 1 |
Transmedics
TMDX
|
+$85.8M |
| 2 |
Keros Therapeutics
KROS
|
+$61.7M |
| 3 |
Legend Biotech
LEGN
|
+$59.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$49.3M |
| 5 |
Geron
GERN
|
+$28M |
Top Sells
| 1 |
Penumbra
PEN
|
+$40.4M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$39M |
| 3 |
Arvinas
ARVN
|
+$31.6M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$30.9M |
| 5 |
DexCom
DXCM
|
+$29.6M |
Sector Composition
| 1 | Healthcare | 66.36% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$17.3B
| $123M | 3.65% |
901,790
-15,884
| -2% | -$1.96M |
|
2
Xenon Pharmaceuticals
XENE
$6.55B
| $114M | 3.39% |
2,913,964
+206,709
| +8% | +$8.55M |
|
|
3
Legend Biotech
LEGN
$4.46B
| $96.9M | 2.87% |
2,977,951
+1,436,400
| +93% | +$59.5M |
|
4
CG Oncology
CGON
$6.44B
| $94.2M | 2.79% |
3,283,317
+112,442
| +4% | +$3.85M |
|
5
Guardant Health
GH
$21.6B
| $87M | 2.58% |
2,847,931
-494,193
| -15% | -$13.9M |
|
6
Align Technology
ALGN
$13B
| $78.2M | 2.32% |
375,179
+63,500
| +20% | +$14.2M |
|
7
Apogee Therapeutics
APGE
$10.2B
| $69.8M | 2.07% |
1,540,362
-102,864
| -6% | -$5.25M |
|
8
Kiniksa Pharmaceuticals
KNSA
$4.75B
| $68.3M | 2.02% |
3,452,447
+557,934
| +19% | +$12.7M |
|
|
APLS
9
DELISTED
Apellis Pharmaceuticals
APLS
| $67M | 1.99% |
2,098,866
-1,026,317
| -33% | -$30.9M |
|
10
iRhythm Holdings
IRTC
$3.72B
| $63.6M | 1.89% |
705,391
-77,166
| -10% | -$6.06M |
|
11
Edgewise Therapeutics
EWTX
$4.39B
| $62.3M | 1.85% |
2,332,196
+373,886
| +19% | +$11.9M |
|
|
DAWN
12
DELISTED
Day One Biopharmaceuticals
DAWN
| $61.8M | 1.83% |
4,873,853
| – | – |
|
13
Spyre Therapeutics
SYRE
$8.86B
| $60M | 1.78% |
2,578,404
+388,568
| +18% | +$11.4M |
|
14
Viking Therapeutics
VKTX
$4.39B
| $59.5M | 1.77% |
1,479,666
+322,689
| +28% | +$18.4M |
|
|
15
Transmedics
TMDX
$2.61B
| $57.5M | 1.7% |
+922,100
| New | +$85.8M |
|
16
Inspire Medical Systems
INSP
$1.46B
| $54.4M | 1.61% |
293,410
+54,499
| +23% | +$10.6M |
|
17
argenx
ARGX
$54B
| $49.7M | 1.47% |
80,766
-15,958
| -16% | -$9.35M |
|
|
18
Thermo Fisher Scientific
TMO
$199B
| $46.7M | 1.38% |
+89,754
| New | +$49.3M |
|
19
Maravai LifeSciences
MRVI
$1.04B
| $45.5M | 1.35% |
8,353,287
| – | – |
|
20
Sarepta Therapeutics
SRPT
$1.86B
| $44.4M | 1.32% |
364,900
-5,500
| -1% | -$674K |
|
|
21
Penumbra
PEN
$12.5B
| $43.7M | 1.29% |
183,828
-177,600
| -49% | -$40.4M |
|
22
Glaukos
GKOS
$9.21B
| $43.3M | 1.28% |
288,876
-22,740
| -7% | -$3.13M |
|
|
AVDL
23
DELISTED
Avadel Pharmaceuticals
AVDL
| $43.2M | 1.28% |
4,105,726
+716,787
| +21% | +$8.7M |
|
24
Repligen
RGEN
$8.35B
| $40.9M | 1.21% |
283,823
-112,958
| -28% | -$16.2M |
|
|
FNA
25
DELISTED
Paragon 28, Inc.
FNA
| $39.6M | 1.17% |
3,834,809
-300,300
| -7% | -$2.42M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM